Hotline: 1800 102 2007
X
Search Business Opportunities
Feb, 10 2017

​Aurobindo acquires four products TL Biopharmaceuticals AG

Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple cancers including metastatic colon or rectal cancer, non-squa

Aurobindo Pharma Limited has announced that it has acquired four cell culture derived biosimilar products from TL Biopharmaceutical AG of Switzerland. The company, however, did not disclose the deal value.

As part of the agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialise and market these products globally.

The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is very promising, the company said. Regulatory filing for these products is intended in the period 2020-22.

Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers.

The transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape, according to the company.

Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars ensuring a strong and diverse products pipeline, it said.

Aurobindo has set up a fully functional R&D center for biologics development and is also establishing a state-of-the-art manufacturing facility in Hyderabad and is expected to be ready by the second quarter of the financial year 2017-18.

N Govindarajan, Managing director, Aurubindo, said in a statement, "We are impressed with the TL product development as these products are developed to the highest standards of biosimilarity. This acquisition is in line with our strategy of investing in complex products and is an important first step towards establishing Aurobindo's global biosimilar portfolio."

Comment
image
Related opportunities
  • Kids & Infant Products
    About Us: Smartspeak is a technological innovation by TransLife Pvt.Ltd, Established..
    Locations looking for expansion New Delhi
    Establishment year 2017
    Franchising Launch Date 2018
    Investment size Rs. 10lac - 20lac
    Space required 300
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Delhi New Delhi
  • Gyms and Fitness Centres
    About Us: VIVAFIT concept is to provide health and well-being in a..
    Locations looking for expansion New Delhi
    Establishment year 2017
    Franchising Launch Date 2017
    Investment size Rs. 30lac - 50lac
    Space required 1500
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater New Delhi New Delhi
  • Lingerie & Innerwear
    About Us: Trylo Inner Luxury - the name says it all.  Trylo..
    Locations looking for expansion Gujarat
    Establishment year 1992
    Franchising Launch Date 2014
    Investment size Rs. 20lac - 30lac
    Space required 400
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Surendranagar Gujarat
  • E-Commerce & Related
    Business Details Nihar Info Global Limited offers their Nihar eCenter System..
    Locations looking for expansion Telangana
    Establishment year 2018
    Franchising Launch Date 2018
    Investment size Rs. 2lac - 5lac
    Space required 200
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Hyderabad Telangana
Insta-Subscribe to
Entrepreneur
Magazine
For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you
OR Click here to Subscribe Online
Daily Updates
Submit your email address to receive the latest updates on news & host of opportunities